Oct 25, 2023 Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting Learn More
Oct 24, 2023 Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023 Learn More
Oct 17, 2023 Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia Learn More
Oct 2, 2023 Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants Learn More